Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 195 entries
View as:

Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)

Phase: N/A Priority: Normal
NCT ID: NCT00967863 Org: User:
Start: 10/31/08 End: 10/31/26 Due: 10/31/27

Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions

Phase: N/A Priority: Normal
NCT ID: NCT05622071 Org: User:
Start: 10/12/23 End: 04/04/28 Due: 04/04/29

Docetaxel in Treating Older Women With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00104624 Org: User:
Start: 05/31/05 End: 07/31/08 Due: 07/31/09

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT00673335 Org: User:
Start: 05/31/08 End: 12/31/23 Due: 12/31/24

COVID-19 Detection Test in Oncology

Phase: N/A Priority: Normal
NCT ID: NCT04367870 Org: User:
Start: 05/23/20 End: 04/30/22 Due: 04/30/23

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02539537 Org: User:
Start: 10/23/15 End: 09/25/23 Due: 09/25/24

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00104715 Org: User:
Start: 10/18/04 End: 12/15/15 Due: 12/15/16

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase: N/A Priority: Normal
NCT ID: NCT00055731 Org: User:
Start: 11/14/02 End: 12/31/22 Due: 12/31/23

Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03143322 Org: User:
Start: 07/24/18 End: 07/22/27 Due: 07/22/28

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Phase: N/A Priority: Normal
NCT ID: NCT02400567 Org: User:
Start: 01/31/15 End: 09/30/20 Due: 09/30/21

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Phase: N/A Priority: Normal
NCT ID: NCT04132960 Org: User:
Start: 10/21/19 End: 12/26/24 Due: 12/26/25

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04747054 Org: User:
Start: 12/01/21 End: 10/01/29 Due: 10/01/30

Chronic Toxicities Related to Treatment in Patients With Localized Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01993498 Org: User:
Start: 02/20/12 End: 03/31/34 Due: 03/31/35

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00470223 Org: User:
Start: 03/31/07 End: 12/31/26 Due: 12/31/27

Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00769405 Org: User:
Start: 02/29/08 End: - Due: -

Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01804790 Org: User:
Start: 01/31/12 End: 07/01/23 Due: 07/01/24

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02980510 Org: User:
Start: 12/31/16 End: 01/31/26 Due: 01/31/27

Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00104741 Org: User:
Start: 09/10/03 End: 10/15/15 Due: 10/15/16

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Phase: N/A Priority: Normal
NCT ID: NCT01442662 Org: User:
Start: 09/30/11 End: 05/28/19 Due: 05/28/20

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06606730 Org: User:
Start: 07/01/25 End: 06/01/39 Due: 06/01/40

Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00423475 Org: User:
Start: 10/31/06 End: - Due: -

Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI

Phase: N/A Priority: Normal
NCT ID: NCT06333314 Org: User:
Start: 07/23/24 End: 09/30/30 Due: 09/30/31

Neoadjuvant Treatment for Advanced Rectal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02551237 Org: User:
Start: 01/07/16 End: 06/30/22 Due: 06/30/23

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Phase: N/A Priority: Normal
NCT ID: NCT04053322 Org: User:
Start: 08/26/19 End: 08/31/27 Due: 08/31/28

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06505018 Org: User:
Start: 07/25/24 End: 09/02/27 Due: 09/02/28